SIRPA and B-cell chronic lymphocytic leukemia: In conclusion, we have identified the SIRPα:Shp1 axis as a selective actionable target that could be exploited using intracellularly and extracellularly directed strategies to enhance ADP responses, by NLCs, to existing therapeutic antibodies in CLL patients.